1. Clinical & Scientific Overview
Buprenorphine (Sublingual & Transdermal) (TIP-MED-000520, Reference Code [R-01]) is classified under
CNS, Pain & Opioid Dependence Therapy as a Partial Mu-Opioid Agonist & Kappa-Opioid Antagonist.
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 / Psychotropic Substance (NDPS Act, 1985).
Addnok-N (Rusan Pharma — with Naloxone), Buvalor (Modi Mundipharma — Transdermal Patch), Bupregesic (Neon Laboratories)
Tablet (Sublingual): 0.2 mg, 0.4 mg, 2 mg, 8 mg; Transdermal Patch: 5 mcg/hr, 10 mcg/hr, 20 mcg/hr; Injection: 0.3 mg/mL
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H1 / Psychotropic Substance (NDPS Act, 1985)
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: Precipitated withdrawal if administered before full opioid agonist washout; additive fatal CNS and respiratory depression when combined with benzodiazepines, alcohol, or gabapentinoids.
Mandatory Dispensing Register & Institutional Custody Protocol: Dispense strictly against valid Schedule H1 / NDPS prescription; retain prescription register copy for 3 years; store in locked controlled drugs cupboard.
3. Mechanism of Action & Pharmacodynamics
High-affinity partial agonist at mu-opioid receptors (MOR) with slow receptor dissociation kinetics and ceiling effect on respiratory depression; antagonist at kappa-opioid receptors (KOR).
4. Therapeutic Indications & Evidence-Supported Uses
- Moderate-to-severe chronic cancer and postoperative pain
- Medically supervised opioid substitution therapy (OST) in opioid use disorder
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Buprenorphine must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Tablet (Sublingual): 0.2 mg, 0.4 mg, 2 mg, 8 mg; Transdermal Patch: 5 mcg/hr, 10 mcg/hr, 20 mcg/hr; Injection: 0.3 mg/mL).
Administration & Meal Timing: Routes: Sublingual, Transdermal, Parenteral (IM/Slow IV). Dispense strictly against valid Schedule H1 / NDPS prescription; retain prescription register copy for 3 years; store in locked controlled drugs cupboard.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits partial mu-opioid agonist & kappa-opioid antagonist pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Buprenorphine or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: Precipitated withdrawal if administered before full opioid agonist washout; additive fatal CNS and respiratory depression when combined with benzodiazepines, alcohol, or gabapentinoids.
8. Adverse Effects Profile
- Precipitated withdrawal if administered before full opioid agonist washout; additive fatal CNS and respiratory depression when combined with benzodiazepines, alcohol, or gabapentinoids.
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- Precipitated withdrawal if administered before full opioid agonist washout; additive fatal CNS and respiratory depression when combined with benzodiazepines, alcohol, or gabapentinoids.
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Precipitated withdrawal if administered before full opioid agonist washout; additive fatal CNS and respiratory depression when combined with benzodiazepines, alcohol, or gabapentinoids.
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Dispense strictly against valid Schedule H1 / NDPS prescription; retain prescription register copy for 3 years; store in locked controlled drugs cupboard.
Pharmacist Patient Counselling Points:
- Dispense strictly against valid Schedule H1 / NDPS prescription; retain prescription register copy for 3 years; store in locked controlled drugs cupboard.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Dispense strictly against valid Schedule H1 / NDPS prescription; retain prescription register copy for 3 years; store in locked controlled drugs cupboard.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.